Back
Proper measurement of renal function is important for diagnosis and stratification of kidney disease. Though several methods have been used to estimate the glomerular filtration rate, results have been variable depending on the population studied. This study was undertaken to estimate and compare different creatinine and cystatin C based GFRs to see their agreement with each other.
This cross-sectional study was conducted on random 222 participants of a rural area. Detail medical history was taken along with available relevant investigations from each patient. The eGFR was estimated using creatinine-based C-G (Cockcroft-Gault), MDRD, CKD-EPI methods and creatinine and cystatin C based formula methods.
Mean age of the study population was 41±12 years with a majority in 31-50 years of age (59%) where male were 53%. Hypertensive subjects were 11% and diabetes was present in 7%. Mean eGFR measured by creatinine based MDRD, C&G (Cockcroft-Gault) and CKD-EPI were 117±25, 102±30 and 119±20 mL/min/1.73 m2 (p=NS). Mean eGFR measured by cystatin C based equation was 107±16 and by both creatinine and cystatin C was 105±20 mL/min/1.73 m2 (p=NS). Comparisons of eGFR by Bland-Altman plot in the study subjects showed some bias between all methods. Here data were skewed and a wide range for the limit of agreement.
The distribution of the frequency of CKD stages varied significantly when each of the formulas applied by creatinine and cystatin C based methods. The stage distribution pattern by MDRD formula of G1, G2 and G3 was 86.5%, 12.6% & 0.9% ; by C-G 68.0%, 22.1% & 9.9% and by CKD-EPI 88.7%, 10.4% & 0.9%. The pattern for cystatin C based formula found only stage G1 and G2 of 87.8% &12.2% . By applying both creatinine and cystatin C it was 76.6% & 23.4%.
GFR estimation methods revealed wide variations when the distribution pattern of CKD stages was done by different creatinine and cystatin C based formulas. Therefore, these GFR estimation methods need to be compared with an ideal measured method to identify the appropriate one.